Orchard Software

January 2012 digital edition January 24, 2012

In this issue
‘Elders’ hang tough against newcomers
Needlestick patrol: breaking bad habits
3 measures beckon more pathologists into PQRS tent
From the President’s Desk:
Center's work reflects Hamilton legacy
Secretary-treasurer, governors to be elected
Coagulation product guide: From the new to the improved
Product guide: Coagulation analyzers
In genetic testing, decoding the
enigma variants
People
Cytopathology and More
Ducks now all in a row in Lean flow cytometry lab
Glucose to Gram stain—new competency tests for 2012
Providing consults in support of the
pain service
Clinical Pathology Abstracts
Anatomic Pathology Abstracts
Q & A
Newsbytes
Classified Advertising
Marketplace
Put it on the Board
New product guides online
Compare and contrast lab instruments and software feature by feature using the online, interactive version of CAP TODAY’s renowned product guides.
Coagulation analyzers
Hematology analyzers
Laboratory information systems
Next-generation sequencing
instruments product
Chemistry analyzers for
low-volume laboratories
Blood bank information systems
Laboratory automation systems
and workcells
In vitro blood gas analyzers
Automated molecular platforms
Chemistry analyzers for mid-
and high-volume laboratories
Positive patient identification products
Automated immunoassay analyzers
Coagulation analyzers—point of care, self-monitoring
Billing/accounts receivable systems
Laboratory-provider links software
Bedside glucose testing systems
Middleware systems
Anatomic pathology computer systems


Regulators scanning the
digital scanners
Karen Titus

A recent panel on whole-slide imaging launched a clear message from the Food and Drug Administration: The agency views WSI systems as Class III medical devices and plans to regulate them as such.

Gentlemen, start your turtles.

While the FDA’s decision was clear, the next steps are anything but. Vendors, pathologists, the FDA, and the Centers for Medicare and Medicaid Services could head in any number of directions next, but they won’t be moving swiftly. In fact, those who were at the meeting are still dissecting the information presented at the panel, as if Alan Greenspan had delivered one of his famously tortured pronouncements from the Federal Reserve.
Of the FDA’s decision to regulate whole-slide imaging systems as Class III devices, Aperio president Dirk Soenksen says, “They’ve made up their mind.... You’re talking five years at the earliest when someone’s going to get approval.” How broad will Aperio's submission be? “As broad as FDA allows,” he says.
Depending on one’s view, the news will slow efforts to bring WSI for primary diagnosis into U.S. laboratories, with some vendors looking to Europe for regulatory relief; have virtually no impact on large vendors, who, while not necessarily enamored of the FDA’s decision, concede it’s one they can live with; kill the market completely; choke innovation among vendors, especially component makers; possibly put laboratories in jeopardy if they try to validate these systems as laboratory-developed tests under CLIA; or encourage laboratories to use WSI for other, already approved purposes, readying themselves for the inevitable day when whole-slide imaging transforms surgical pathology. [more]






captodayonline.com


MORE INFORMATION

NOT A SUBSCRIBER?
For more information about our digital edition, please access our Frequently Asked Questions page. Access our online form to request your complimentary CAP TODAY magazine subscription. Stay informed on emerging issues through feature articles, concise news items, regular columns, and scientific abstracts. Subscribe or renew now.
©2012 CAP TODAY, all rights reserved.
The appearance of advertising in this message is not a CAP guarantee or endorsement of the product or the claims made for the product by the manufacturer. If you wish to be removed from this mailing list, go to http://leda.cap.org/UM/U.asp?B1.421.20085.270426 and you will be removed immediately. Thank you.